George Marzouka, MD

Dr Marzouka is a practicing non-invasive Cardiologist, an assistant professor of medicine, and a medical writer. After graduating from medical school at the University of Miami, he completed his internal medicine residency and cardiology fellowship at Jackson Memorial Hospital, the University of Miami, and the Miami VA healthcare system. During his training he became focused on clinical research, quality of care, and outcomes within cardiology which lead him to acquire several large national datasets from the National Heart, Lung, and Blood Institute (NHLBI) from which he has published numerous peer-reviewed manuscripts and presented over a dozen abstracts at both the American College of Cardiology (ACC) and American Heart Association (AHA). Further he has authored a text book chapter on Guidelines and Appropriate Use Criteria for nuclear cardiac imaging. After completing his post-graduate training, Dr. Marzouka spent a year in private practice before returning to academia where he now specializes in cardiac imaging, teaches, and treats high risk cardiovascular patients after discharge. His research continues to evaluate new cardiovascular drug therapies for heart failure while using predictive analytic techniques to help clinicians identify habits, behaviors, and other factors that cause or protect against cardiovascular diseases.

Most Recent Articles by George Marzouka, MD

The American Health Care Act — Is It the Best We Can Do?

The American Health Care Act — Is It the Best We Can Do?

By

Republicans are not looking at the problems with the ACA, nor are they trying to find real solutions. The only Americans they seem to serve are those who need the ACA the least.

Higher Premiums and the Affordable Care Act — Why the ACA Isn't to Blame

Higher Premiums and the Affordable Care Act — Why the ACA Isn't to Blame

By

Republicans have capitalized on the misunderstood concept that the ACA is responsible for their health premiums going up and misleading voters to turn them against the ACA.

FOURIER Trial Reviewed: Are the Expensive PCSK9 Inhibitors Right for Your Patients?

FOURIER Trial Reviewed: Are the Expensive PCSK9 Inhibitors Right for Your Patients?

By

At the current price of the drug, and lacking sufficient mortality data, treating patients for longer periods of time with expensive PCSK9 inhibitors is likely to result only in large profits for the company.

A Look at Cruz's Arguments on the ACA Debate

A Look at Cruz's Arguments on the ACA Debate

By

Is the aim of our health-care system to care for human beings or to generate profits for corporations?

Coronary Artery Calcium Scores - A Marker for Early Adverse Events in Young Patients?

Coronary Artery Calcium Scores - A Marker for Early Adverse Events in Young Patients?

By

More research is needed to determine the downstream effects of applying such a prediction model to the general population.

More Articles by George Marzouka, MD

Free E-Newsletter